Rituximab News and Research

RSS

Rituximab is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of B-cell non-Hodgkin lymphoma. It is also approved to be used with methotrexate to treat rheumatoid arthritis. Rituximab is also being studied in the treatment of other types of cancer and other conditions.

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Verastem, Inc., focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the National Comprehensive Cancer Network added COPIKTRA (duvelisib) capsules to the Clinical Practice Guidelines in Oncology (NCCN Guidelines) for follicular lymphoma.

8 Oct 2018

$CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL$

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

AbbVie, a research-based global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion for VENCLYXTO® in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia who have received at least one prior therapy.

21 Sep 2018

Scientists discover key aspect in the development of multiple sclerosis

In multiple sclerosis, not only the T cells of the immune system, but also its B cells, play an important role.

7 Sep 2018

Researchers discover key aspect in pathogenesis of multiple sclerosis

A team of researchers the University of Zurich and the University Hospital Zurich has shown that in multiple sclerosis, it is not only specific T cells that cause inflammation and lesions in the brain.

4 Sep 2018

Study shows B cells could play reciprocal roles in pathogenesis of systemic sclerosis

Systemic sclerosis (SSc, also known as scleroderma), a connective tissue disorder of autoimmune etiology, is characterized by excessive fibrosis in the skin and various internal organs.

30 Aug 2018

AbbVie submits supplemental NDA to FDA for venetoclax to treat acute myeloid leukemia

AbbVie, a research-based global biopharmaceutical company, today announced it submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for venetoclax in combination with a hypomethylating agent or in combination with low-dose cytarabine for the treatment of newly diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.

20 Jul 2018

CTI BioPharma announces Phase III results of PIXUVRI combined with rituximab in aggressive B-cell NHL patients

CTI BioPharma Corp. and Servier today announced that the pivotal Phase III study evaluating PIXUVRI® combined with rituximab in comparison to gemcitabine combined with rituximab in patients with aggressive B-cell non-Hodgkin lymphoma did not meet its primary endpoint of improvement of progression-free survival

9 Jul 2018

Drug used to treat myelofibrosis can awaken ‘dormant’ lymphomas in the bone marrow

Most patients with myelofibrosis, a rare chronic disorder of the haematopoietic cells of the bone marrow, benefit from drugs from the JAK2 inhibitor class: symptoms are relieved, survival extended and general quality-of-life enhanced.

18 Jun 2018

Celgene to share new and updated data around novel hematological therapies

Celgene Corporation today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association annual meeting in Stockholm, Sweden, from June 14-17, 2018.

22 May 2018

Chemist begins new project to develop carbohydrate mimics to assist cancer therapies

Dr. Robert Britton firmly believes every molecule is important. This chemist doesn't want any molecule sitting unused on a laboratory shelf or in a fridge.

18 May 2018

New studies could offer novel treatments for vision and eye conditions

Three new studies demonstrate research findings that could offer novel treatments for vision and eye conditions.

30 Apr 2018

HEV infections can be fatal and transmitted through blood products in immunosuppressed patients

Hepatitis E virus infection is once again in the spotlight, with two studies presented today at The International Liver Congress 2018 in Paris, France challenging the ideas that HEV infections are benign and self-limiting, and that blood-borne transmission is a rare event.

12 Apr 2018

Early and targeted treatment of dnDSA preserves allograft function

Development of de novo donor-specific antibodies (dnDSA) is known to cause graft failure. Therefore, a protocol aimed at prospective monitoring and treating dnDSA--before it can cause graft damage--was developed for kidney transplant recipients at Children National Health System.

5 Feb 2018

Combination of chemotherapy and targeted drug improves response in younger CLL patients

Among younger patients newly diagnosed with chronic lymphocytic leukemia (CLL), treatment with a combination of chemotherapy and a molecularly targeted drug significantly improves response over what is typically seen with chemotherapy alone, according to an investigator-initiated multi-center phase II clinical trial.

11 Dec 2017

Southampton researchers find new approach to reverse treatment resistance in lymphoma patients

Researchers from the University of Southampton have identified why some people may become resistant to monoclonal antibodies, a common type of immunotherapy used in lymphoma treatment.

17 Jul 2017

Adding new antibody to chemotherapy could bolster effects of cancer treatment

Adding an investigational antibody to the chemotherapy rituximab appears to restore its cancer-killing properties in certain leukemia patients with a natural resistance to the drug, according to a small, proof-of-concept study by Duke Cancer Institute researchers.

29 Jun 2017

ACR, AAHKS release new guideline to reduce joint infections after total hip and knee replacements

According to a new guideline released by the American College of Rheumatology and American Association of Hip and Knee Surgeons, the risk of joint infection resulting from total hip and knee replacements can be reduced with careful management of anti-rheumatic medications during the perioperative process.

16 Jun 2017

Study finds no clear benefit of stem-cell transplant for double-hit lymphoma patients in remission

Patients with double hit lymphoma (DHL) who undergo autologous stem-cell transplantation (autoSCT) after achieving remission are not more likely to remain in remission or live longer than patients who do not undergo autoSCT, according to a new analysis from the Perelman School of Medicine and the Abramson Cancer Center of the University of Pennsylvania.

15 May 2017

WHO to launch pilot project for prequalifying biosimilar cancer medicines

This year WHO will launch a pilot project for prequalifying biosimilar medicines, a step towards making some of the most expensive treatments for cancer more widely available in low- and middle-income countries.

8 May 2017

New technique opens door for biochemists to create better therapeutic antibodies

Antibodies are the foot soldiers of our immune system. These specialized, Y-shaped proteins attach to bacteria and viruses, where they either block the pathogen's activity directly, or signal the immune system's cells to destroy the invader.

14 Mar 2017